Improving Healthcare Access CSR News

[WEBINAR] Reimagining Community Health Systems: Join SAP, Medtronic Foundation, and Leading Nonprofits in Community Health (Thurs, 10/15, 12 - 1 EDT)

Multimedia with summary

Join SAP, Medtronic, National Association of Community Health Centers, Iowa Primary Care Association, and PYXERA Global on October 15, 12pm-1pm EDT. Learn how cross-sector collaboration is breaking down healthcare barriers to make telehealth more accessible to the 30 million Americans who rely on Community Health Centers. Register today! 

Dow Awarded 2020 NSC Green Cross Safety Innovation Award

Press Release

MIDLAND, Mich., October 13, 2020 /3BL Media/ – Dow (NYSE: DOW) announced recently that it has been awarded the 2020 National Safety Council (NSC) Green Cross for Safety® Innovation Award.

Dow received the NSC Green Cross for Safety® Innovation Award during the 2020 Green Cross for Safety Awards virtual celebration on October 1 for its Aerial Lift Safety Project, for approaching a lasting challenge and developing a transformative response to the problem.

Mohawk Goes Pink: Doing Our Part For a Cure

Multimedia with summary

Since 2001, Mohawk Industries has contributed more than $6 million to Susan G. Komen, the largest breast cancer research organization in the United States. Through corporate donation programs including Decorate for the Cure and Specify for a Cure — as well as different employee-led initiatives — we are committed to this ongoing partnership to one day find a cure.

How a Local Agency Removes the Barriers That Keep Underserved Families in Poverty

In one of the country’s most impoverished regions, a local nonprofit and a Truist Cares* grant bring hope and opportunity to single-parent households, homeless youth, and others in need.
Blog

In February 2020, while most of America enjoyed 3.5% unemployment and unprecedented economic prosperity, Kentucky resident Iyeshia Lattimore was barely getting by.

Johnson & Johnson Joins Other Companies in Signing a Landmark Communiqué on Expanded Global Access for COVID-19

Summary: 

In signing the communiqué, Johnson & Johnson and 15 other life science companies are committing to prioritize the safety, science and accessibility of the potential vaccines, therapeutic medicines or diagnostic tools they are developing to help fight the pandemic.

Article

In signing the communiqué, Johnson & Johnson and 15 other life science companies are committing to prioritize the safety, science and accessibility of the potential vaccines, therapeutic medicines or diagnostic tools they are developing to help fight the pandemic.

Aflac Contributes $1.5 Million to Sickle Cell Disease Program at the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta

Press Release

COLUMBUS, Ga., /3BLMedia/ - September was National Sickle Cell Awareness Month, and Aflac, a leader in supplemental insurance sales at U.S. worksites, today announced the company's 2020 annual contribution of $1.5 million to the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta has been earmarked for the hospital's Sickle Cell Disease Program. The Aflac Cancer Center hosts the largest sickle cell program in the United States. To date, Aflac has given more than $6 million to the Aflac Cancer and Blood Disorders Center's Sickle Cell Disease Program.

New Sensory Room at New Hope Middle School 'a Safe Space' for Special Needs Students

By Ryan Anderson
Article

New Hope Middle School officially opened its new Kodiak Calming Cove, a sensory room for children with special needs, recently, and "it'll make a big difference for students to have a safe space they can go into," said Belinda Sloan, the school's principal.

Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate

First participants dosed in Phase 3 trial (ENSEMBLE) evaluating safety and efficacy of Janssen’s COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S
Press Release

NEW BRUNSWICK, N.J., September 28, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) recently announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies. The initiation of the ENSEMBLE trial follows positive interim results from the Company’s Phase 1/2a clinical study, which demonstrated that the safety profile and immunogenicity after a single vaccination were supportive of further development.

Factories, Face Masks and the New Back To School

SCOTT LENNOX, Principle Scientist Chocolate PD, Research and Development
Blog

There are a lot of expressions for agreement in the workplace.

You can be “on board,” or “get behind” or “buy into” something. It’s good to be “on the same page,” or “coming from the same place,” with your colleagues. In my role in Research and Development with The Hershey Company, we like to “lean in,” to a lot of things.

Pages

Subscribe to Improving Healthcare Access